Year-to-date performance in AMRN is lagging the biotech index, but analysts note potential catalysts in EU approvals. The amrn stock forecast could shift sharply upward upon credible partnership announcements. Over the past 90 days, revenue estimates for the full year 2024 have declined from $207.24 million to $206.53 million, and for 2025, estimates have decreased from $208.62 million to $180.04 million. Earnings estimates for the full year 2024 have improved from -$0.20 per share to -$0.14 per share, and for 2025, earnings estimates have been adjusted from -$0.19 per share to -$0.18 per share. In this article, we will take a look at the 12 best penny stocks to buy under $1. To see more such companies, go directly to 5 Best Penny Stocks to Buy Under $1 . Biotech ETFs have been showing net inflows, with AMRN one of the mid-cap constituents benefiting from passive investment. The amrn stock forecast integrates these flows as incremental bullish pressure.